top of page
< Back

Mimi-Q presents first results at ESTIV conference

Andrey Poloznikov

25. Nov. 2022

Driving Innovation in Anticancer Treatment Evaluation: Mimi-Q GmbH Showcases Groundbreaking Results at ESTIV 2022 in Barcelona-Sitges, Spain

Barcelona-Sitges, Spain – Mimi-Q GmbH is proud to announce the successful presentation of its poster, titled "PK-driven drug test for the evaluation of the efficacy of anticancer treatment regimens," at the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022) in Barcelona-Sitges, Spain. The congress, which was held from 21st to 25th November 2022, brought together leading experts in the field of toxicology and drug development. The poster, which was presented by Andrey Poloznikov, Mimi-Q GmbH, showcased Mimi-Q´s approach to evaluating the efficacy of anticancer treatment regimens ultimately leading to better outcomes for patients. Mimi-Q GmbH would like to thank ESTIV for the opportunity to share our innovative approach to anticancer treatment evaluation with the leading experts in the field at ESTIV 2022 and the congress organizers for hosting such a successful event. "The positive feedback and interest we received is a testament to the hard work and dedication of our team and we are excited to continue to push the boundaries of drug development and improve patient outcomes," said Andrey Poloznikov, Mimi-Q GmbH´s CTO. We look forward to continuing to be a part of and contribute to the advancement of the field of toxicology in vitro.

bottom of page